Cargando…
A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies
Although several new therapeutic approaches have improved outcomes in the treatment of hematologic malignancies, unmet need persists in acute myeloid leukemia (AML), multiple myeloma (MM) and non-Hodgkin's lymphoma. Here we describe the proteomic identification of a novel cancer target, SAIL (S...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476018/ https://www.ncbi.nlm.nih.gov/pubmed/26024286 http://dx.doi.org/10.1038/bcj.2015.39 |
_version_ | 1782377535656427520 |
---|---|
author | Kim, S Y Theunissen, J-W Balibalos, J Liao-Chan, S Babcock, M C Wong, T Cairns, B Gonzalez, D van der Horst, E H Perez, M Levashova, Z Chinn, L D‘Alessio, J A Flory, M Bermudez, A Jackson, D Y Ha, E Monteon, J Bruhns, M F Chen, G Migone, T-S |
author_facet | Kim, S Y Theunissen, J-W Balibalos, J Liao-Chan, S Babcock, M C Wong, T Cairns, B Gonzalez, D van der Horst, E H Perez, M Levashova, Z Chinn, L D‘Alessio, J A Flory, M Bermudez, A Jackson, D Y Ha, E Monteon, J Bruhns, M F Chen, G Migone, T-S |
author_sort | Kim, S Y |
collection | PubMed |
description | Although several new therapeutic approaches have improved outcomes in the treatment of hematologic malignancies, unmet need persists in acute myeloid leukemia (AML), multiple myeloma (MM) and non-Hodgkin's lymphoma. Here we describe the proteomic identification of a novel cancer target, SAIL (Surface Antigen In Leukemia), whose expression is observed in AML, MM, chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). While SAIL is widely expressed in CLL, AML, MM, DLBCL and FL patient samples, expression in cancer cell lines is mostly limited to cells of AML origin. We evaluated the antitumor activity of anti-SAIL monoclonal antibodies, 7-1C and 67-7A, conjugated to monomethyl auristatin F. Following internalization, anti-SAIL antibody–drug conjugates (ADCs) exhibited subnanomolar IC(50) values against AML cell lines in vitro. In pharmacology studies employing AML cell line xenografts, anti-SAIL ADCs resulted in significant tumor growth inhibition. The restricted expression profile of this target in normal tissues, the high prevalence in different types of hematologic cancers and the observed preclinical activity support the clinical development of SAIL-targeted ADCs. |
format | Online Article Text |
id | pubmed-4476018 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-44760182015-06-30 A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies Kim, S Y Theunissen, J-W Balibalos, J Liao-Chan, S Babcock, M C Wong, T Cairns, B Gonzalez, D van der Horst, E H Perez, M Levashova, Z Chinn, L D‘Alessio, J A Flory, M Bermudez, A Jackson, D Y Ha, E Monteon, J Bruhns, M F Chen, G Migone, T-S Blood Cancer J Original Article Although several new therapeutic approaches have improved outcomes in the treatment of hematologic malignancies, unmet need persists in acute myeloid leukemia (AML), multiple myeloma (MM) and non-Hodgkin's lymphoma. Here we describe the proteomic identification of a novel cancer target, SAIL (Surface Antigen In Leukemia), whose expression is observed in AML, MM, chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). While SAIL is widely expressed in CLL, AML, MM, DLBCL and FL patient samples, expression in cancer cell lines is mostly limited to cells of AML origin. We evaluated the antitumor activity of anti-SAIL monoclonal antibodies, 7-1C and 67-7A, conjugated to monomethyl auristatin F. Following internalization, anti-SAIL antibody–drug conjugates (ADCs) exhibited subnanomolar IC(50) values against AML cell lines in vitro. In pharmacology studies employing AML cell line xenografts, anti-SAIL ADCs resulted in significant tumor growth inhibition. The restricted expression profile of this target in normal tissues, the high prevalence in different types of hematologic cancers and the observed preclinical activity support the clinical development of SAIL-targeted ADCs. Nature Publishing Group 2015-05 2015-05-29 /pmc/articles/PMC4476018/ /pubmed/26024286 http://dx.doi.org/10.1038/bcj.2015.39 Text en Copyright © 2015 Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Original Article Kim, S Y Theunissen, J-W Balibalos, J Liao-Chan, S Babcock, M C Wong, T Cairns, B Gonzalez, D van der Horst, E H Perez, M Levashova, Z Chinn, L D‘Alessio, J A Flory, M Bermudez, A Jackson, D Y Ha, E Monteon, J Bruhns, M F Chen, G Migone, T-S A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies |
title | A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies |
title_full | A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies |
title_fullStr | A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies |
title_full_unstemmed | A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies |
title_short | A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies |
title_sort | novel antibody–drug conjugate targeting sail for the treatment of hematologic malignancies |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476018/ https://www.ncbi.nlm.nih.gov/pubmed/26024286 http://dx.doi.org/10.1038/bcj.2015.39 |
work_keys_str_mv | AT kimsy anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT theunissenjw anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT balibalosj anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT liaochans anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT babcockmc anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT wongt anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT cairnsb anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT gonzalezd anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT vanderhorsteh anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT perezm anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT levashovaz anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT chinnl anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT dalessioja anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT florym anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT bermudeza anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT jacksondy anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT hae anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT monteonj anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT bruhnsmf anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT cheng anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT migonets anovelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT kimsy novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT theunissenjw novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT balibalosj novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT liaochans novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT babcockmc novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT wongt novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT cairnsb novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT gonzalezd novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT vanderhorsteh novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT perezm novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT levashovaz novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT chinnl novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT dalessioja novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT florym novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT bermudeza novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT jacksondy novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT hae novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT monteonj novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT bruhnsmf novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT cheng novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies AT migonets novelantibodydrugconjugatetargetingsailforthetreatmentofhematologicmalignancies |